2020
DOI: 10.3390/cancers12123725
|View full text |Cite
|
Sign up to set email alerts
|

Development of a Prognostic Tool to Guide the Decision to Extend Adjuvant Aromatase Inhibitors for up to Ten Years in Postmenopausal Early Breast Cancer Patients

Abstract: Background: The selection of women with hormone receptor-positive (HR+) early breast cancer (EBC) at high risk of relapse after five years (yrs.) of adjuvant aromatase inhibitors (AIs) is crucial, as the benefit of extending AIs is counterbalanced by toxicity. We developed a clinicopathological tool to estimate the residual risk of relapse after five years of adjuvant AIs. Methods: The Institut de Cancérologie de l’Ouest (ICO) database was used to determine a prognostic score of post-five-year AI relapse. Cox … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
2
0

Year Published

2021
2021
2023
2023

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(2 citation statements)
references
References 45 publications
0
2
0
Order By: Relevance
“…Moreau-Bachelard et al developed the Clinical Treatment Score post-5 years (CTS5), a prognostic tool that predicts the risk of distant recurrence after 5 years of treatment with tamoxifen for early breast cancer [ 19 ]. The CTS5 is intended for use to guide decision making surrounding extended use of adjuvant aromatase inhibitors (AI).…”
Section: Resultsmentioning
confidence: 99%
See 1 more Smart Citation
“…Moreau-Bachelard et al developed the Clinical Treatment Score post-5 years (CTS5), a prognostic tool that predicts the risk of distant recurrence after 5 years of treatment with tamoxifen for early breast cancer [ 19 ]. The CTS5 is intended for use to guide decision making surrounding extended use of adjuvant aromatase inhibitors (AI).…”
Section: Resultsmentioning
confidence: 99%
“…Baseline characteristics of tools included in a systematic review of prognostic tools for older patients with breast cancer[10][11][12][13][14][15][16][17][18][19][20][21][22][23][24][25][26].…”
mentioning
confidence: 99%